Compare Natera Inc. Common Stock (NTRA) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs TKO Group Holdings Inc — how do they compare? Natera Inc. Common Stock trades at $394.6 (market cap $57.03B), while TKO Group Holdings Inc trades at $173.56 (market cap $12.71B). The key difference: Natera Inc. Common Stock is far larger — about 4.5× TKO Group Holdings Inc's market cap, and TKO Group Holdings Inc pays a 1.82% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and TKO Group Holdings Inc for 31 Days on average.
| NTRA | TKO | |
|---|---|---|
Market Cap | $57.03B | $12.71B |
Volume | 1,131,157 | 835,872 |
Sector | Health | Media |
52-Week High | $425.64 | $224.96 |
52-Week Low | $179.42 | $172.38 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $56.18B | $17.07B |
Dividend Yield | — | 1.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
TKO trades at $173.86, near a 52-week low, with a bearish technical signal. The company reported mixed Q2 2026 earnings, missing EPS estimates but raising full-year guidance. Revenue growth is solid, with 2026 projected at $5.3B, though profitability remains modest with a net margin of 4.33%. Analyst sentiment is overwhelmingly positive, with a consensus price target of $227.00 and 89% buy ratings, but recent institutional selling and technical weakness suggest near-term caution.
The outlook is cautiously optimistic; strong media rights and franchise value underpin long-term growth, but high valuation multiples and recent price decline highlight execution risks. Investors should weigh robust analyst confidence against technical bearishness and margin pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
